Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity

Eur Respir J. 1999 Mar;13(3):647-53. doi: 10.1183/09031936.99.13364799.

Abstract

This study examined the safety of sputum induction and the relation between sputum cell counts and clinical parameters in adolescents with severe persistent asthma. Within 5 days, induced sputum and reversibility in forced expiratory volume in one second (FEV1), quality of life, provocative concentration causing a 20% fall in FEV1 (PC20) of adenosine monophosphate and histamine, exercise-induced bronchoconstriction, overall asthma severity index, and blood eosinophils were collected in 20 atopic adolescents with moderate-to-severe persistent asthma (12-18 yrs of age, FEV1 65-110% of predicted, on 500-2,000 microg inhaled steroids daily). FEV1 was reversible by 13.3-2.3% pred. After sputum induction, FEV1 was still increased by 9.0+/-2.6% pred as compared to the pre-salbutamol baseline. Sputum contained, median (range): 12.4 (0.4-59.5)% squamous cells, 47.3 (6.8-84.0)% macrophages, 39.0 (4.6-84.8)% neutrophils, 4.8 (1.0-12.4)% lymphocytes, 0.4 (0-10.8)% eosinophils and 3.6 (0-23.4)% bronchial epithelial cells. Sputum eosinophils showed a trend towards a significant association with the overall asthma severity index (r=0.46, p=0.06) and correlated inversely with baseline FEV1 (r=-0.51, p=0.03). In conclusion, sputum can be induced safely in adolescents with moderate-to-severe persistent asthma, if pretreated with beta2-agonists. Despite relatively low sputum eosinophil counts in these patients on inhaled steroids, the association of eosinophil numbers with baseline forced expiratory volume in one second and asthma severity index favours a role of induced sputum in monitoring adolescents with severe asthma.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Albuterol
  • Asthma / diagnosis*
  • Biomarkers / analysis
  • Blood Proteins / analysis*
  • Bronchial Provocation Tests
  • Cell Count
  • Cross-Sectional Studies
  • Diagnostic Techniques and Procedures / adverse effects
  • Eosinophil Granule Proteins
  • Female
  • Humans
  • Inflammation Mediators / analysis*
  • Male
  • Monitoring, Physiologic / methods
  • Prognosis
  • Quality of Life
  • Reproducibility of Results
  • Respiratory Function Tests
  • Ribonucleases*
  • Sputum / chemistry
  • Sputum / cytology*

Substances

  • Biomarkers
  • Blood Proteins
  • Eosinophil Granule Proteins
  • Inflammation Mediators
  • Ribonucleases
  • Albuterol